Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine versus gemcitabine + capecitabine in advanced pancreatic cancer
ISRCTN11513444Phase 3Completed
- Sponsor
- Sponsor not defined
- Start
- Apr 2002
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in pancreatic cancer (PC) comparing Gemcitabine alone with Gemcitabine + capecitabine (2 arms). Primary endpoint: One-year survival. Started Apr 2002; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ISRCTN11513444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11513444.